Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

Report Scope:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents, and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments; droplet digital PCR (polymerase chain reaction); target enrichment; single-cell DNA polymerase; non-invasive prenatal testing (NIPT); fetal-cell NIPT; CTC (circulating tumor cell) capture and detection; and liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics, and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring), and geography (North America, Europe, Asia/Pacific, Rest of World).

Market data covers 2017, 2018 and 2023 (forecasted).

More than 175 companies in the liquid biopsy industry are profiled in this report.

A Summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.

Report Includes:

- 32 data tables and 54 additional tables
- Industry analysis of the liquid biopsy biomarkers and technologies market
- Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
- Discussion of several significant large-scale research initiatives that are contributing to liquid biopsy market development
- Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
- Company profiles of major manufacturers and suppliers of liquid biopsy research tools, services and diagnostics, including Agilent Technologies Inc., Cygnus Biosciences, Illumina Inc., Oxford Nanopore, Qiagen, Quantum Biosystems, Roche and Thermo Fisher Scientific


Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary
Chapter 3 Overview
Introduction
Report Scope
Liquid Biopsy Versus Traditional Biopsy
Markets
Forces Driving Growth
Key Trends
Industry
Chapter 4 Technology Background
Liquid Biopsy Biomarkers
Cancer Genomics
Non-Invasive Prenatal Testing
Circulating Tumor Cell Technologies
CTC Workflow
Cell Isolation Technologies
CTC Sample Preparation Technologies
CTC Downstream Analysis Technologies
Comparison of Liquid Biopsy with Conventional Biopsy
Cancer Testing
Prenatal Testing
Chapter 5 Liquid Biopsy Initiatives
Blood Profiling Atlas
Cancer-ID
CTC Trap Consortium
Early Cancer Detection Consortium
EpiFemCare
Human Cell Atlas
Immunomonitor Consortium
Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
Liquid Biopsies and Imaging for Improved Cancer Care
Next-Generation Single-Cell Analysis Program
Population Sequencing Projects
Precancer Atlas
Precision Medicine Initiative
Single-Cell Proteomics and Lipidomics Project
TopMed
Worldwide Innovative Networking (WIN) Consortium
Single-Cell Research
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
Chapter 6 Market Breakdown by End User
Introduction
Cancer Applications
Precision Medicine
Cancer Biomarker Status
Cancer Market Segments
Reproductive Health Applications
Transplant Diagnostics Applications
Chapter 7 Liquid Biopsy Industry
Advanced Sequencing Instruments Industry
Droplet Digital PCR Industry
Target Enrichment and Amplification Industry
Single-Cell DNA Polymerase Industry
Non-Invasive Prenatal Testing Industry
Fetal Cell NIPT Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry
Chapter 8 Industry Acquisitions and Strategic Alliances
Acquisitions
Strategic Alliances
Key Trends
2017 Alliances
2018 Alliances
Chapter 9 Liquid Biopsy Markets
Forces Driving Growth
Liquid Biopsy Market by Indication
Liquid Biopsy Market by Biomarker Type
Liquid Biopsy Market by Analysis Platform
Liquid Biopsy Market by Analysis Purpose
Non-Invasive Prenatal Testing Market
Cancer Markets
Cancer Market by Indication
Cancer Market by Analysis Purpose
Cancer Market by Biomarker Class
Cancer Market by Analysis Method
Breast Cancer Market
Colorectal Cancer Market
Hematological Cancer Market
Lung Cancer Market
Pan-cancer Market
Transplant Markets
Regional Market Analysis
Chapter 10 Patent Review/ New Developments
Circulating Tumor Cell Patents
Exosome Patents
Cell-free DNA Patents
Liquid Biopsy and Sequencing-related Patent Issues
Chapter 11 Company Profiles
ACCURAGEN, INC.
ADAPTIVE BIOTECHNOLOGIES INC.
ADVANCED CELL DIAGNOSTICS INC.
AGILENT TECHNOLOGIES INC.
AKADEUM LIFE SCIENCES
ALCEDIAG
AMOY DIAGNOSTICS CO. LTD.
ANGLE PLC
APOCELL INC.
APOSTLE INC.
ARCEDI BIOTECH APS
ARUP LABORATORIES
ASURAGEN INC.
ATRECA INC.
AVIVA BIOSCIENCES
BAYLOR GENETICS
BECTON, DICKINSON AND CO.
BELLWETHER BIO INC.
BERRY GENOMICS CO. LTD.
BGI SHENZHEN
BIOCARTIS NV
BIOCEPT INC.
BIOCORE CO. LTD.
BIODESIX INC.
BIOFLUIDICA INC.
BIOGAZELLE
BIOMARX INC.
BIO-RAD LABORATORIES INC.
BIO-TECHNE LTD.
BIOVENDOR–LABORATORNI MEDICINA A.S.
BLUESTAR GENOMICS INC.
BOREAL GENOMICS
CANCER GENETICS INC.
CAREDX INC.
CEGAT GMBH
CELLMAX LIFE
CELL MICROSYSTEMS INC.
CELSEE DIAGNOSTICS
CHRONIX BIOMEDICAL
CIRCULOGENE THERANOSTICS
CIRCULOMICS INC.
CLINICAL GENOMICS TECHNOLOGIES
CODIAK BIOSCIENCES
COLOR GENOMICS
CS GENETICS LTD.
CYGNUS BIOSCIENCES CO. LTD.
CYNVENIO BIOSYSTEMS INC.
CYTOTRACK APS
DATAR CANCER GENETICS LTD.
DIACARTA INC.
DIAGNOLOGIX LLC
DIAGNOMICS
DIRECT GENOMICS CO. LTD.
DNA ELECTRONICS LTD.
DNALYTICS
DNANEXUS INC.
DOVETAIL GENOMICS LLC
ENVISION GENOMICS
EPIC SCIENCES INC.
EUROFINS SCIENTIFIC
EXACT SCIENCES CORP.
EXOSOME SCIENCES INC.
EXPEDEON AG
EZLIFE BIO INC.
FABRIC GENOMICS
FLUXION BIOSCIENCES INC.
FREENOME INC.
GENAPSYS INC.
GENEDX INC.
GENESEQ BIOSCIENCES PTY LTD.
GENETICS RESEARCH LLC
GENOMATIX GMBH
GENOMIC HEALTH INC.
GENOMONCOLOGY
GENOSPACE
GENEXOSOME TECHNOLOGIES INC.
GIGAGEN INC.
GOLDEN HELIX
GRAIL INC.
GUARDANT HEALTH INC.
HELITEC
HELIX OPCO LLC
HTG MOLECULAR DIAGNOSTICS INC.
ILLUMINA INC.
IMMUNOVIA AB
INEX INNOVATIONS EXCHANGE PTE. LTD.
INIVATA LTD.
INTERPACE DIAGNOSTICS LLC
INVITAE INC.
INVIVOSCRIBE INC.
JBS SCIENCE INC.
KONINKLIJKE PHILIPS N.V.
LABORATORY CORP. OF AMERICA INC.
LEXENT BIO INC.
LUCENCE DIAGNOSTICS PTE. LTD.
MAMMOTH BIOSCIENCES INC.
MDNA LIFE SCIENCES INC.
MDXHEALTH INC.
MEDGENOME LABS PVT. LTD.
MEDOMICS LLC
MENARINI SILICON BIOSYSTEMS SPA
MERCK KGAA
MOLECULAR HEALTH GMBH
MYRIAD GENETICS INC.
NAMOCELL INC.
NANOSTRING TECHNOLOGIES INC.
NANOVIEW BIOSCIENCES INC.
NATERA INC.
NAVERIS INC.
NEOGENOMICS LABORATORIES
NEW ENGLAND BIOLABS
NEW ONCOLOGY GMBH
NIPD GENETICS
N-OF-ONE INC.
NOVOGENE CO. LTD.
NUGEN TECHNOLOGIES INC.
NUPROBE INC.
NX PRENATAL INC.
ONCOCYTE CORP.
ONCODNA S.A.
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PANGAEA ONCOLOGY
PARADIGM DIAGNOSTICS INC.
PARSEQ LAB CO. LTD.
PATHWAY GENOMICS CORP.
PERSONAL GENOME DIAGNOSTICS INC.
PIERIANDX
PORTABLE GENOMICS LLC
PRECIPIO INC.
PREDICINE INC.
PREMAITHA HEALTH PLC
PRENETICS
PROVISTA DIAGNOSTICS INC.
QIAGEN NV
QUANTAPORE INC.
QUANTUM BIOSYSTEMS INC.
QUANTUMDX
QUEST DIAGNOSTICS INC.
RARECELLS SAS
RARECYTE INC.
REAL TIME GENOMICS INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
SCREENCELL
SEEKIN
SENGENICS LTD.
SEQUENCING.COM
SEVEN BRIDGES GENOMICS INC.
SINGLERA GENOMICS INC.
SOPHIA GENETICS
SPERA MEDICAL
SPHERE FLUIDICS LTD.
STILLA TECHNOLOGIES
STRAND LIFE SCIENCES PVT. LTD.
STRATOS GENOMICS INC.
SYAPSE
SYSMEX INOSTICS GMBH
TAI DIAGNOSTICS INC.
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TRANSPLANT GENOMICS
TROVAGENE INC.
TWINSTRAND BIOSCIENCES
TWO PORE GUYS INC.
TYMORA ANALYTICAL OPERATIONS LLC
UBIQUITY GENOMICS INC.
VORTEX BIOSCIENCES
XING TECHNOLOGIES LLC
VELA DIAGNOSTICS
VOLITIONRX
VORTEX BIOSCIENCES
YIKON GENOMICS CO. LTD.


List Of Tables


Summary Table : Global Liquid Biopsy Market, by Disease Class, Through 2023
Table 1 : Liquid Biopsy Sample Types
Table 2 : Liquid Biopsy Report Scope
Table 3 : Global Liquid Biopsy Market, by Analysis Type, Through 2023
Table 4 : Forces Driving Growth
Table 5 : Key Trends in Liquid Biopsy Market
Table 6 : Liquid Biopsy Industry Subsectors
Table 7 : Liquid Biopsy Biomarker Classes
Table 8 : Single-Cell Analysis to Identify Cancer Driver Mutations
Table 9 : Genomics-based Oncology Workflow
Table 10 : Unique Challenges of CTC Capture and Analysis
Table 11 : CTC Workflow
Table 12 : Cell Differentiators
Table 13 : Cell Isolation Technologies
Table 14 : CTC Sample Preparation Technologies
Table 15 : Single-Cell Analysis Technologies
Table 16 : Estimated Annual Solid Biopsy Procedures Performed in the United States for Selected Cancers
Table 17 : Main Risks for Needle-based Tissue Biopsies
Table 18 : Factors in Tissue Biopsy
Table 19 : Prenatal Invasive Testing Technologies
Table 20 : Invasive Versus Non-invasive Prenatal Technologies
Table 21 : Key Liquid Biopsy Research and Development Programs
Table 22 : Single-Cell Core Research Facilities
Table 23 : Source of Foreign Biomarkers for Liquid Biopsy Applications
Table 24 : Personalized Medicine Driven by Common Cancer Genetic Mutations
Table 25 : Cancer Liquid Biopsy Biomarker Clinical Status
Table 26 : Cancer Liquid Biopsy Market Segments
Table 27 : Reproductive Health Screening Applications
Table 28 : Ethical Issues Associated with NIPT
Table 29 : Transplant Diagnostics Applications
Table 30 : Key Segments and Trends within the Liquid Biopsy Industry
Table 31 : Advanced Sequencing Industry Company Positioning
Table 32 : End-to-End Sequencing Approaches
Table 33 : Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 34 : Digital PCR Liquid Biopsy Industry
Table 35 : Target Enrichment Industry
Table 36 : Single-Cell DNA Polymerase Industry
Table 37 : NIPT Industry
Table 38 : Estimated Market Share for NIPT, 2018
Table 39 : Germany NGS-based Non-invasive Prenatal Diagnostic Companies, 2017
Table 40 : NIPT Test Licensing, by Country
Table 41 : Fetal Cell NIPT Industry
Table 42 : CTC Separations Industry
Table 43 : Liquid Biopsy Assay Industry: Company Focus
Table 44 : Example of NGS-based Liquid Biopsy Market Differentiation
Table 45 : Liquid Biopsy Industry Acquisitions, January 2017-November 2018
Table 46 : Liquid Biopsy Strategic Alliances, January 2017-November 2018
Table 47 : Liquid Biopsy Key Forces Driving Growth and Implications, 2023
Table 48 : Global Liquid Biopsy Market, by Indication, Through 2023
Table 49 : Global Liquid Biopsy Market, by Biomarker Type, Through 2023
Table 50 : FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 51 : Global Liquid Biopsy Market, by Analysis Platform, Through 2023
Table 52 : Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
Table 53 : Global NIPT Market, by Analysis Purpose, Through 2023
Table 54 : Global NIPT Market, by Risk Type, Through 2023
Table 55 : Global NIPT Market, by Biomarker Class, Through 2023
Table 56 : Global NIPT Market, by Analysis Method, Through 2023
Table 57 : Limitations of Solid Biopsy in Cancer Applications
Table 58 : Low-Frequency Mutation Detection
Table 59 : Global Liquid Biopsy Cancer Market, by Indication, Through 2023
Table 60 : Five-year Survival Rate for Ovarian Cancer
Table 61 : National Institutes of Health Liquid Biopsy Early Detection Initiative
Table 62 : Molecular Thyroid Nodule Classifier Test Company Positioning
Table 63 : Global Liquid Biopsy Cancer Market, by Analysis Purpose, Through 2023
Table 64 : MRI and Liquid Biopsy Methods
Table 65 : Early Detection Tissue of Origin Approaches
Table 66 : Global Liquid Biopsy Cancer Market, by Biomarker Class, Through 2023
Table 67 : Global Liquid Biopsy Cancer Market, by Analysis Method, Through 2023
Table 68 : Global Breast Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 69 : Global Colorectal Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 70 : Hematological Cancer Market, by Analysis Method, Through 2023
Table 71 : Global Lung Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 72 : Global Pan-cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 73 : Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2023
Table 74 : Global Liquid Biopsy Transplant Market, by Organ Type, Through 2023
Table 75 : Transplant Procedures Performed in the United States, 2016 to 30 Sept. 2018
Table 76 : Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2023
Table 77 : Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2023
Table 78 : Global Liquid Biopsy Market, by Region, Through 2023
Table 79 : Global Cancer Liquid Biopsy Market, by Region, Through 2023
Table 80 : Global NIPT Liquid Biopsy Market, by Region, Through 2023
Table 81 : Global Transplant Liquid Biopsy Market, by Region, Through 2023
Table 82 : Patent Activity for Circulating Tumor Cells (CTCs), by Country/Region, 2008-2018
Table 83 : Patent Activity for Exosomes, by Country/Region, 2008-2018
Table 84 : Patent Activity for Cell-free DNA (cfDNA), by Country/Region, 2008-2018
Table 85 : Status of Liquid Biopsy and Sequencing-related Patent Disputes


List Of Figures


Summary Figure : Global Liquid Biopsy Market, by Disease Class, 2017-2023
Figure 1 : How Cancer Genomics Drives Liquid Biopsy


Global Liquid Biopsy Market Research Report 2019-2023

A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. In the context of China-US trade war

USD 2850 View Report

Europe Breast Cancer Liquid Biopsy Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Breast Cancer Liquid Biopsy market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Global Liquid Biopsy Market Research Report 2019-2023

A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. In the context of China-US trade war

USD 2850 View Report

Europe Breast Cancer Liquid Biopsy Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Breast Cancer Liquid Biopsy market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available